Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 186

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Immunogenicity and Smoking-Cessation Outcomes for a Novel Nicotine Immunotherapeutic

Open access
Hatsukami, D K, Jorenby, D E, Gonzales, D, Rigotti, N A, Glover, E D, Oncken, C A, Tashkin, D P, Reus, V I, Akhavain, R C, Fahim, R E F, Kessler, P D, Niknian, M, Kalnik, M W, Rennard, S I · 2011 · Clinical Pharmacology & Therapeutics

Abstract

NicVAX, a nicotine vaccine (3'AmNic-rEPA), has been clinically evaluated to determine whether higher antibody (Ab) concentrations are associated with higher smoking abstinence rates and whether dosages and frequency of administration are associated with increased Ab response. This randomized, double-blinded, placebo-controlled multicenter clinical trial (N = 301 smokers) tested the results of 200- and 400-µg doses administered four or five times over a period of 6 months, as compared with placebo. 3'AmNic-rEPA recipients with the highest serum antinicotine Ab response (top 30% by area under the curve (AUC)) were significantly more likely than the placebo recipients (24.6% vs. 12.0%, P = 0.024, odds ratio (OR) = 2.69, 95% confidence interval (CI), 1.14-6.37) to attain 8 weeks of continuous abstinence from weeks 19 through 26. The five-injection, 400-µg dose regimen elicited the greatest Ab response and resulted in significantly higher abstinence rates than placebo. This study demonstrates, as proof of concept, that 3'AmNic-rEPA elicits Abs to nicotine and is associated with higher continuous abstinence rates (CAR). Its further development as a treatment for nicotine dependence is therefore justified.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/clpt.2010.317

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 186

Metadata

Authors
Hatsukami, D. K., Jorenby, D. E., Gonzales, D., Rigotti, N. A., Glover, E. D., Oncken, C. A., Tashkin, D. P., Reus, V. I., Akhavain, R. C., Fahim, R. E. F., Kessler, P. D., Niknian, M., Kalnik, M. W., & Rennard, S. I.
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2011-01-26
Volume
89
Issue
3
Pages
392-399
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
OpenAlex
W2130197019
Cited by
186
References
3
FWCI
13.68
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunogenicity and Smoking-Cessation Outcomes for a Novel Nicotine Immunotherapeutic. https://app.cochat.ai/papers/10.1038/clpt.2010.317
The paper
Hatsukami, D. K., Jorenby, D. E., Gonzales, D., Rigotti, N. A., Glover, E. D., Oncken, C. A., Tashkin, D. P., Reus, V. I., Akhavain, R. C., Fahim, R. E. F., Kessler, P. D., Niknian, M., Kalnik, M. W., & Rennard, S. I. (2011). Immunogenicity and Smoking-Cessation Outcomes for a Novel Nicotine Immunotherapeutic. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/clpt.2010.317

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.